Mon to Sun 9:00 am to 12:00 am

Karachi, Pakistan

ASCO: Lilly exec points to ‘nutty’ 100% response rate for in vivo CAR-T as justifying Kelonia buyout - Fierce Biotech

ASCO: Lilly exec points to ‘nutty’ 100% response rate for in vivo CAR-T as justifying Kelonia buyout - Fierce Biotech

By Darren Incorvaia | Published: May 31, 2026

No additional content available.

Read Full Article
whatsapp
SCROLL TO TOP